Welcome to our dedicated page for Cumberland Pharmaceuticals news (Ticker: CPIX), a resource for investors and traders seeking the latest updates and insights on Cumberland Pharmaceuticals stock.
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) is a specialty pharmaceutical company whose news flow centers on its portfolio of FDA-approved brands and its clinical development programs. The company focuses on hospital acute care, gastroenterology, and oncology markets, and its announcements often highlight product milestones, commercialization agreements, and study results that affect how its medicines are used in practice.
Recent news has covered developments for Caldolor (ibuprofen) injection, including a permanent CMS J-code associated with a reimbursement price that supports its use as a non-opioid option for managing pain and fever. Cumberland has also reported regulatory approval of its ibuprofen injection product in Mexico through a partnership with PiSA Farmaceutica, reflecting the company’s efforts to expand access to its hospital acute care therapies internationally.
Another recurring theme in CPIX news is the expansion of Vibativ (telavancin) injection. Press releases describe new supply arrangements and group purchasing agreements with organizations such as Vizient and Premier in the United States, as well as the launch of Vibativ in Saudi Arabia through Tabuk Pharmaceutical Manufacturing Company. These updates explain how hospitals and providers can access Vibativ in different configurations and markets.
Cumberland’s news also highlights its ifetroban Phase II clinical programs in Duchenne Muscular Dystrophy cardiomyopathy, Systemic Sclerosis, and Idiopathic Pulmonary Fibrosis, including presentations of trial data and regulatory interactions. In addition, investors can follow revenue updates and quarterly financial results, which break down net revenues by product such as Kristalose, Sancuso, Vibativ, and Caldolor.
For readers tracking CPIX, the news stream provides insight into product-level performance, international partnerships, reimbursement developments, and the progress of late-stage clinical studies. Bookmarking this page can help investors, clinicians, and other stakeholders follow key events affecting Cumberland’s commercial portfolio and pipeline.
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) reported third quarter 2020 net revenues of $9.3 million, up from $6.9 million year-over-year. The firm also recorded $750,000 from divested product rights. Total assets stood at $96 million with $27 million in cash. The company has launched new initiatives including the FDA-approved RediTrex and expanded use of Vibativ for COVID-19 patients. However, net income for Q3 was a loss of $(0.5) million or $(0.03) per share, a slight improvement from $(2.0) million in the previous year.
Cumberland Pharmaceuticals (NASDAQ: CPIX) will announce its third quarter 2020 financial results on Nov. 10, 2020, after market close. A conference call, including a live webcast, is scheduled for the same day at 4:30 p.m. ET. The company develops and commercializes prescription brands for acute care, gastroenterology, and oncology. Its FDA-approved products include Acetadote and Kristalose, among others. Currently, Cumberland is conducting Phase II clinical trials for its ifetroban candidates targeting multiple diseases.
Cumberland Pharmaceuticals (NASDAQ: CPIX) announced results from a review of clinical studies on Caldolor® (ibuprofen) Injection published in Clinical Therapeutics. The review included 1,062 adult patients and found that Caldolor leads to a quicker plasma concentration, enhances postoperative recovery, and reduces opioid and over-the-counter medication use. The study supports the incorporation of Caldolor into Enhanced Recovery After Surgery protocols. CEO A.J. Kazimi emphasized its role in reducing opioid use amid ongoing efforts to address opioid consumption in healthcare.
Cumberland Pharmaceuticals (NASDAQ: CPIX) reported second quarter 2020 net revenues of $9.6 million from ongoing operations, up from $9.4 million year-over-year. Total revenues were $10.3 million, boosted by $750,000 from divested product rights. The Company's financial position showed $97.5 million in total assets, $49.1 million in liabilities, and $48.5 million in shareholders' equity. Net income for Q2 was a loss of $(0.9) million, equating to $(0.06) per share, while adjusted earnings improved to $1.2 million or $0.08 per diluted share. Cumberland continued to support healthcare during COVID-19 with product supply initiatives.
Cumberland Pharmaceuticals Inc. (CPIX) will release its second quarter 2020 financial results and company update on August 11, 2020, after market close. A conference call is scheduled for the same day at 4:30 p.m. ET to discuss these results. The company focuses on developing and commercializing prescription brands in hospital acute care, gastroenterology, and oncology via targeted sales forces. Their FDA-approved products include Acetadote, Caldolor, Kristalose, and more, with ongoing Phase II programs for ifetroban in DMD, SSc, and AERD.
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced the results of a study published in the Journal of Orthopedic Trauma, demonstrating that Caldolor ® (ibuprofen injection) significantly reduces opioid use for pain management in orthopedic trauma patients. Conducted at a Level 1 Trauma Center, the randomized trial involved 99 patients receiving either 800 mg IV ibuprofen or a placebo. Results indicated a longer time to first narcotic medication and lower pain intensity at 8 hours in the Caldolor group. This research highlights a potential alternative to opioids in emergency pain management.